ازدياد حساسية خلايا سرطان القولون و المستقيم Caco-2 للدوكسوروبيسين نتيجة مشاركته مع أحد مثبطات إنزيم الألدوز ريدوكتاز

Abstract EN

Doxorubicin is classified within the anthracyclines family.

an active, wide-spectrum and cost effective drug group, which is used in the treatment of many types of cancers such as breast cancer, bladder cancer and lymphoma, without being used in the treatment of colorectal cancer, because of the resistance of these cancer cells to anthracyclines, which at higher doses cause cardiotoxicity.

our research aims to study the possibility of using anthracyclines in the treatment of colorectal cancer.

the study was conducted in-vitro on colorectal cancer cell line (Caco-2).

aldose reductase enzyme was inhibited using fidarstat using different concentrations.

our results showed that the use of fidarstat increased the sensitivity of colorectal cancer cells (Caco-2) to doxorubicin, as well as reduced the half-inhibitory dose (IC50) of doxorubicin from 7.07 um to 3.08 um.

our results also showed that the increase in sensitivity is time-dependent but concentration-independent.

this study supports the use fidarstat as an adjuvant therapy with doxorubicin in colorectal cancer treatment protocols.